The financials
10x Genomics, Inc. by the numbers
10x Genomics, Inc. (TXG) reported revenue of $151M in Q1 2026 (quarter ended March 31, 2026), down 2.6% from the same quarter a year earlier. That came with a gross margin of 70% and net loss of $13M. For the full year FY2025, revenue was $643M (+5.2% year on year) and net income −$44M. Its largest product in 2026-Q1 was Chromium Consumables at $89M, 55% of the disclosed total, just ahead of Spatial Consumables at 25%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $151M | $155M | −2.6% |
| Gross profit | $106M | $105M | +0.7% |
| Operating income | −$17M | −$39M | n/a |
| Net income | −$13M | −$34M | n/a |
| Diluted EPS | −$0.10 | −$0.28 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Chromium Consumables | $89M | 55% |
| Spatial Consumables | $41M | 25% |
| Instruments | $11M | 6.9% |
| Service | $8.8M | 5.4% |
| Spatial Instruments | $6.0M | 3.7% |
| Chromium Instruments | $5.2M | 3.2% |
| Licensing And Royalty | $947K | 0.6% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $162.1M (+0.69%)
Spatial Consumables grew +31% year on yearLicensing And Royalty -94% year on year
Segment Latestquarter on quarteryear on year
- Chromium Consumables$88.9M$88.9MQoQ -3.9%year on year +5.7%-3.9%+5.7%
- Spatial Consumables$40.9M$40.9MQoQ +16%year on year +31%+16%+31%
- Instruments$11.3M$11.3MQoQ -6.1%year on year -24%-6.1%-24%
- Service$8.8M$8.8MQoQ +8.7%year on year +15%+8.7%+15%
- Spatial Instruments$6.0M$6.0MQoQ -15%year on year -32%-15%-32%
- Chromium Instruments$5.2M$5.2MQoQ +6.0%year on year -12%+6.0%-12%
- Licensing And Royalty$947.0K$947.0KQoQ -3.7%year on year -94%-3.7%-94%
Health Information Services
Ranks #2 of 14 by Smart Score